GRP78 in viral pneumonia: dual regulatory mechanisms and translational prospects Authors: Hang Ruan, Qian-Rui Huang, Li-Juan Zou, Shu-Sheng Li Published: 2026 ABSTRACT Glucose-regulated protein 78 (GRP78), a core molecular chaperone governing the endoplasmic reticulum (ER) stress response, exerts dual regulatory effects during the pathogenesis of viral pneumonia. Beyond serving as a critical cofactor that promotes viral invasion and replication, GRP78 functions as an indispensable protective chaperone that preserves pulmonary cellular homeostasis and attenuates lung injury. This review characterizes two distinct subcellular localizations of GRP78 in viral pneumonia, namely ER-resident GRP78 and cell surface GRP78 (csGRP78), and systematically summarizes its dual regulatory mechanisms. Specifically, csGRP78 mediates viral adhesion and internalization, whereas ER-GRP78 promotes viral replication and aggravates pulmonary inflammation by modulating ER stress and the unfolded protein response. Meanwhile, GRP78 alleviates pulmonary tissue damage via suppressing lung cell apoptosis and restraining excessive ERS activation. Moreover, this review provides a comprehensive overview of advances in GRP78-targeted therapeutic strategies. The covered therapeutic modalities include small-molecule inhibitors, biological macromolecular drugs, indirect regulatory compounds, and natural products. This review also elaborates their specific molecular targets, core mechanisms, and preclinical findings. Additionally, the current research trends, existing limitations, and future perspectives of GRP78-related investigations are critically discussed. This review aims to clarify the central regulatory role of GRP78 in viral pneumonia, providing theoretical basis and innovative research directions for the precision targeted therapy of viral pneumonia. Introduction Viral pneumonia triggered by influenza, respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a critical global health threat [1]. The 2021 Global Burden of Disease Study documented over 344 million annual cases of lower respiratory infections worldwide, with bacterial and viral pathogens collectively representing the leading aetiological drivers [2, 3]. Viral pneumonia is a leading cause of intensive care unit admission, acute respiratory distress syndrome (ARDS) and infection-related mortality [2]. In the United States, 100,000–150,000 elderly patients are hospitalised for RSV each year, with in-hospital mortality of 4–7% and frequent long-term pulmonary complications [4]. Even with modern critical care improvements, COVID-19-associated ARDS carries a dramatically high in-hospital case fatality of approximately 48% in large nationwide cohorts [5]. Conventional regimens based on broad-spectrum antivirals and corticosteroids cannot effectively balance viral clearance with host tissue protection, creating an urgent demand for novel molecular targets to co-regulate viral replication and immune-mediated tissue damage [6, 7]. Viral invasion hijacks host protein synthesis, inducing endoplasmic reticulum (ER) accumulation of viral glycoproteins and misfolded proteins to trigger endoplasmic reticulum stress (ERS) [8]. Persistent unfolded protein response (UPR) activation further fuels excessive inflammation and epithelial apoptosis, establishing ERS as a core pathological hub in viral lung injury [8, 9]. As a key member of the heat shock protein 70 family, glucose-regulated protein 78 (GRP78, also termed BiP) acts as the central regulator of ERS. It sustains calcium balance and protein folding under physiological conditions, while its expression is sharply upregulated during viral infection to determine cellular fate [10–13]. GRP78 plays a dual, context-dependent role in viral pneumonia [14]. Functioning as an endogenous cytoprotective factor, it orchestrates adaptive UPR signaling to restrict alveolar epithelial apoptosis and dampen inflammatory responses [15]. In contrast, viruses utilise GRP78 to achieve immune evasion: cell-surface GRP78 (csGRP78) serves as a vital entry co-receptor for SARS-CoV-2 and other viruses, and sustained GRP78 upregulation promotes viral replication and may exacerbate inflammatory injury [16–18]. The molecular determinants governing GRP78’s functional dichotomy remain incompletely defined, with polarity likely dictated by disease stage, viral burden, and cellular context. This review distinguishes itself from the expanding body of literature on GRP78 in COVID-19 by providing a systematic dissection of cell-type-specific and phase-dependent biphasic regulation of GRP78 across the full spectrum of viral pneumonia—positioning it not merely as a viral entry facilitator but as a dynamically toggling node between host defense and pathogenesis. By integrating subcellular localization, immune cell-specific functions, and temporal phase dynamics, we establish a clinically actionable framework. Furthermore, we critically evaluate the translational gap of GRP78-targeted therapeutics, addressing real-world bottlenecks in pulmonary delivery, spatiotemporal selectivity, and compensatory resistance mechanisms that have been overlooked in prior reviews. Figure 1 illustrates the core functions of GRP78 and the overall conceptual framework of this review. Fig. 1The multifaceted role of GRP78 dysregulation in viral pneumonia. Persistent endoplasmic reticulum stress (ERS) induced by viral infection triggers glucose-regulated protein 78 (GRP78) dysregulation and subcellular redistribution in lung cells. The conformational transformation from endoplasmic reticulum-resident GRP78 (ER-GRP78) to cell-surface GRP78 (csGRP78) is the core pathological feature. The dysregulated GRP78 drives viral pneumonia progression via three key mechanisms: (1) Viral invasion: csGRP78 acts as a host co-receptor to facilitate viral adhesion, internalization and replication; (2) Immune disorder: Aberrant GRP78 expression disrupts the unfolded protein response (UPR) signaling, triggering inflammatory imbalance and sustaining pulmonary immunosuppressive microenvironment; (3) Pulmonary cellular injury: Excessive ERS activates C/EBP homologous protein (CHOP)-dependent apoptotic cascades, inducing alveolar epithelial and endothelial damage, pulmonary barrier disruption and severe pneumonia deterioration The multifaceted role of GRP78 dysregulation in viral pneumonia. Persistent endoplasmic reticulum stress (ERS) induced by viral infection triggers glucose-regulated protein 78 (GRP78) dysregulation and subcellular redistribution in lung cells. The conformational transformation from endoplasmic reticulum-resident GRP78 (ER-GRP78) to cell-surface GRP78 (csGRP78) is the core pathological feature. The dysregulated GRP78 drives viral pneumonia progression via three key mechanisms: (1) Viral invasion: csGRP78 acts as a host co-receptor to facilitate viral adhesion, internalization and replication; (2) Immune disorder: Aberrant GRP78 expression disrupts the unfolded protein response (UPR) signaling, triggering inflammatory imbalance and sustaining pulmonary immunosuppressive microenvironment; (3) Pulmonary cellular injury: Excessive ERS activates C/EBP homologous protein (CHOP)-dependent apoptotic cascades, inducing alveolar epithelial and endothelial damage, pulmonary barrier disruption and severe pneumonia deterioration GRP78 molecular structure and regulatory pathways GRP78’s dual regulatory effects in viral pneumonia stem from its molecular plasticity and functional heterogeneity [14]. Rather than being a static ER homeostasis regulator, GRP78 undergoes dynamic subcellular relocalization in response to microenvironmental changes, executing opposing biological functions that underlie its simultaneous roles in host defense and viral facilitation [10, 19]. GRP78 molecular structure and functional plasticity Core molecular structure GRP78, encoded by the HSPA5 gene, is a central member of the HSP70 family and the predominant molecular chaperone in the ER lumen [20]. Its structure comprises three critical domains: N-terminal ATPase domain (NBD), substrate-binding domain (SBD), and C-terminal ER retention signal (KDEL) [21, 22]. Under physiological conditions, GRP78 binds misfolded proteins via SBD, utilizes ATP hydrolysis by NBD for protein repair, and simultaneously suppresses the three ERS transmembrane sensors (PERK, IRE1α, ATF6), maintaining ER calcium homeostasis and protein quality control [10, 19]. During viral infection, GRP78 undergoes significant functional reprogramming driven by: (1) dynamic subcellular translocation from ER to plasma membrane and nucleus, conferring non-canonical functions [23, 24], and (2) precise regulation by post-translational modifications (PTMs) including S-palmitoylation, SUMOylation, and O-glycosylation, which determine its functional trajectory in stress responses [10, 25, 26]. Subcellular localization-dependent functional heterogeneity GRP78’s functional versatility is governed by subcellular localization, extending well beyond its traditional ER confinement: (1) Liquid–liquid phase separation (LLPS): Recent evidence demonstrates that GRP78 forms dynamic condensates via LLPS under ERS, efficiently concentrating misfolded proteins or viral components to enhance protein quality control [27]. (2) csGRP78: Under conditions of stress or viral infection, GRP78 undergoes translocation to the plasma membrane via non-classical secretion or exosomal anchoring, where it forms complexes with CD44 variants and integrin β1.While preserving its chaperone activity, csGRP78 acquires signaling competence, activating Src, FAK, and PI3K/AKT cascades to modulate inflammation, cell migration, and fibrosis [28, 29]. (3) Nuclear GRP78: Properly processed GRP78 translocates to the nucleus under stress, losing chaperone activity but functioning as a transcriptional co-regulator that binds cis-elements to modulate genes involved in cellular invasion, metabolism, and stress adaptation [25, 30]. Pathological relevance to viral pneumonia In viral pneumonia, GRP78 exhibits distinct biological functions dependent on its subcellular localization. Briefly, ER-resident GRP78 modulates alveolar epithelial cell fate via UPR signaling, while csGRP78 participates in viral adhesion and immune recognition. Additionally, nuclear GRP78 mediates cellular stress adaptation through transcriptional regulation [30–32].Under sustained ERS, GRP78 undergoes subcellular translocation from the ER lumen to the cell surface to execute extracellular biological functions [33]. Such localization-dependent functional diversity is derived from the stress-induced surface translocation of HSPA5-encoded GRP78, enabling this protein to broadly regulate viral infection, cellular stress, immune response and lung tissue repair [10]. GRP78-mediated ERS pathway: core pathological hub in viral pneumonia Respiratory viral invasion of alveolar epithelial and vascular endothelial cells drives pathogenesis through two intertwined cascades: viral hijacking of host protein synthesis causing structural damage, and excessive host immune activation triggering cytokine storms that disrupt the alveolar-capillary barrier, ultimately progressing to ARDS and multiple organ dysfunction [7, 34]. ERS and its mediated UPR serve as the intracellular nexus connecting these pathways. During robust viral replication, structural proteins accumulate within the rough ER, inducing proteotoxic stress and consequently activating the three UPR sensors [31, 35]. Concurrently, reactive oxygen species (ROS) and pro-inflammatory cytokines from inflammatory cascades disrupt ER redox homeostasis, creating a positive feedback loop of viral replication-inflammation-ERS [36]. A retrospective cohort study encompassing 180 hospitalized COVID-19 patients from two regional centers demonstrated that elevated serum GRP78 was a significant predictor of pneumonia development, exhibiting robust discriminative performance (AUC ≈ 0.71) across both cohorts [37]. UPR activation follows a biphasic pattern: moderate activation triggers adaptive responses via the PERK-eIF2α-ATF4, IRE1α-XBP1, and ATF6 branches, promoting cell survival through upregulated chaperone synthesis and enhanced clearance of misfolded proteins [34, 38]. However, persistent or excessive ERS redirects UPR signaling toward pro-apoptotic programming, inducing alveolar epithelial apoptosis and pyroptosis through CHOP upregulation and caspase cascade activation, thereby amplifying lung injury [34]. GRP78 serves as the master upstream regulator of this hub. In resting state, GRP78 binds and inactivates PERK, IRE1α, and ATF6; upon ERS, GRP78 dissociates from sensors to bind unfolded proteins, triggering UPR cascades [10, 39]. In viral pneumonia patients, GRP78 mRNA and protein levels are significantly upregulated in lung tissues, accompanied by dynamic subcellular relocalization [40, 41]. Through its non-canonical functions, GRP78 integrates viral replication, cytokine storms, and lung injury, establishing itself as the central regulatory node in viral pneumonia pathogenesis [33, 42, 43]. Figure 2 illustrates the principal regulatory pathways of GRP78, which are fundamentally associated with endoplasmic reticulum stress. Fig. 2Major regulatory pathways of GRP78 involved in endoplasmic reticulum stress. This figure illustrates the regulatory network of GRP78 under physiological and stress conditions. (1) Physiological state: ER-localized GRP78 maintains cellular homeostasis via chaperone function. It binds and inhibits three UPR sensors (PERK, IRE1α, ATF6) to prevent excessive UPR activation and cell apoptosis. (2) Sustained ERS state: The dissociation of GRP78 activates three canonical UPR pathways to modulate GRP78 transcription: PERK pathway: Activated protein kinase R-like ER kinase (PERK) phosphorylates eukaryotic initiation factor 2α (eIF2α) to upregulate activating transcription factor 4 (ATF4) and initiate GRP78 transcription; ATF6 pathway: Cleaved activating transcription factor 6α (cATF6α) binds to ER stress response elements (ERSE) to promote GRP78 expression; IRE1α pathway: Activated inositol-requiring enzyme 1α (IRE1α) mediates X-box binding protein 1 (XBP1) mRNA splicing, and spliced XBP1 (XBP1s) further enhances GRP78 transcription. Collectively, these cascades regulate ER-associated degradation (ERAD) to restore ER homeostasis. → = Activation / Promotion; ⊣ = Inhibition / Suppression Major regulatory pathways of GRP78 involved in endoplasmic reticulum stress. This figure illustrates the regulatory network of GRP78 under physiological and stress conditions. (1) Physiological state: ER-localized GRP78 maintains cellular homeostasis via chaperone function. It binds and inhibits three UPR sensors (PERK, IRE1α, ATF6) to prevent excessive UPR activation and cell apoptosis. (2) Sustained ERS state: The dissociation of GRP78 activates three canonical UPR pathways to modulate GRP78 transcription: PERK pathway: Activated protein kinase R-like ER kinase (PERK) phosphorylates eukaryotic initiation factor 2α (eIF2α) to upregulate activating transcription factor 4 (ATF4) and initiate GRP78 transcription; ATF6 pathway: Cleaved activating transcription factor 6α (cATF6α) binds to ER stress response elements (ERSE) to promote GRP78 expression; IRE1α pathway: Activated inositol-requiring enzyme 1α (IRE1α) mediates X-box binding protein 1 (XBP1) mRNA splicing, and spliced XBP1 (XBP1s) further enhances GRP78 transcription. Collectively, these cascades regulate ER-associated degradation (ERAD) to restore ER homeostasis. → = Activation / Promotion; ⊣ = Inhibition / Suppression core role of GRP78 in viral pneumonia initiation During the initial infection phase of viral pneumonia, csGRP78 is abnormally upregulated and serves as a critical mediator for respiratory pathogen invasion of host lung epithelial cells, establishing infection and initiating disease progression [32, 33]. csGRP78 enhances viral adhesion, endocytosis, and intracellular trafficking through multiple mechanisms, significantly increasing infection efficiency and providing the pathological foundation for subsequent viral replication, immune activation, and disease progression [13, 44]. csGRP78 has been identified as a universal host factor for multiple pneumonia-causing respiratory viruses, representing a promising target for broad-spectrum antiviral strategies [45, 46]. Table 1 illustrates the diverse array of viruses involving GRP78 and delineates its functional roles throughout the viral infection process [13, 18, 31, 32, 40, 47–59]. Table 1Core roles and molecular mechanisms of GRP78 in pathogenic virus infections associated with viral pneumoniaVirus familyVirus subtypeCore GRP78 functionsCore molecular mechanismsKey validation evidenceReferencesCoronaviridaeSARS-CoV-2Entry co-receptor + core host dependency factorcsGRP78 binds S protein RBD, forms complex with ACE2 to mediate cellular entry; facilitates viral protein folding and replicationGRP78 knockdown/inhibition suppresses viral replication; clinical levels positively correlate with disease severity[13, 18, 32, 40]OrthomyxoviridaeInfluenza A virusEntry co-receptor + key host factorcsGRP78 binds HA protein to mediate entry; regulates ERS-UPR pathway mediating lung epithelial damageHSPA5 knockdown significantly inhibits viral infection efficiency[31, 47–49]FlaviviridaeDENVCore component of receptor complex + host factorcsGRP78 mediates cellular entry; facilitates viral intracellular proliferationGRP78 silencing significantly inhibits viral invasion and replication[50, 51]FlaviviridaeZIKVKey host factor for invasioncsGRP78 binds envelope E protein to mediate entry; assists viral replicationAnti-GRP78 antibodies/knockdown block viral infection[52, 53]FiloviridaeEBOVEssential host factor for replicationBinds viral GP1 protein for cellular entry; facilitates intracellular viral replicationGRP78 knockdown inhibits viral replication and protects animal models[54, 55]TogaviridaeCHIKVHost dependency factorFacilitates viral protein folding and replication via UPR pathwayAndrographolide mitigates UPR and apoptosis in CHIKV infection[56, 57]ParamyxoviridaeMeVViral glycoprotein chaperoneInteracts with viral glycoproteins to assist folding and intracellular traffickingModulation of GRP78 upstream pathways inhibits viral infection[58, 59]ACE2, angiotensin-converting enzyme 2; CHIKV, Chikungunya virus; csGRP78, cell surface glucose-regulated protein 78; DENV, Dengue virus; EBOV, Ebola virus; ERS, endoplasmic reticulum stress; HA, hemagglutinin; HSPA5, GRP78 encoding gene; MeV, Measles virus; RBD, receptor-binding domain; S protein, spike protein; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; UPR, unfolded protein response; ZIKV, Zika virus Table 1Core roles and molecular mechanisms of GRP78 in pathogenic virus infections associated with viral pneumoniaVirus familyVirus subtypeCore GRP78 functionsCore molecular mechanismsKey validation evidenceReferencesCoronaviridaeSARS-CoV-2Entry co-receptor + core host dependency factorcsGRP78 binds S protein RBD, forms complex with ACE2 to mediate cellular entry; facilitates viral protein folding and replicationGRP78 knockdown/inhibition suppresses viral replication; clinical levels positively correlate with disease severity[13, 18, 32, 40]OrthomyxoviridaeInfluenza A virusEntry co-receptor + key host factorcsGRP78 binds HA protein to mediate entry; regulates ERS-UPR pathway mediating lung epithelial damageHSPA5 knockdown significantly inhibits viral infection efficiency[31, 47–49]FlaviviridaeDENVCore component of receptor complex + host factorcsGRP78 mediates cellular entry; facilitates viral intracellular proliferationGRP78 silencing significantly inhibits viral invasion and replication[50, 51]FlaviviridaeZIKVKey host factor for invasioncsGRP78 binds envelope E protein to mediate entry; assists viral replicationAnti-GRP78 antibodies/knockdown block viral infection[52, 53]FiloviridaeEBOVEssential host factor for replicationBinds viral GP1 protein for cellular entry; facilitates intracellular viral replicationGRP78 knockdown inhibits viral replication and protects animal models[54, 55]TogaviridaeCHIKVHost dependency factorFacilitates viral protein folding and replication via UPR pathwayAndrographolide mitigates UPR and apoptosis in CHIKV infection[56, 57]ParamyxoviridaeMeVViral glycoprotein chaperoneInteracts with viral glycoproteins to assist folding and intracellular traffickingModulation of GRP78 upstream pathways inhibits viral infection[58, 59]ACE2, angiotensin-converting enzyme 2; CHIKV, Chikungunya virus; csGRP78, cell surface glucose-regulated protein 78; DENV, Dengue virus; EBOV, Ebola virus; ERS, endoplasmic reticulum stress; HA, hemagglutinin; HSPA5, GRP78 encoding gene; MeV, Measles virus; RBD, receptor-binding domain; S protein, spike protein; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; UPR, unfolded protein response; ZIKV, Zika virus Core roles and molecular mechanisms of GRP78 in pathogenic virus infections associated with viral pneumonia ACE2, angiotensin-converting enzyme 2; CHIKV, Chikungunya virus; csGRP78, cell surface glucose-regulated protein 78; DENV, Dengue virus; EBOV, Ebola virus; ERS, endoplasmic reticulum stress; HA, hemagglutinin; HSPA5, GRP78 encoding gene; MeV, Measles virus; RBD, receptor-binding domain; S protein, spike protein; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; UPR, unfolded protein response; ZIKV, Zika virus molecular mechanisms of csGRP78-mediated viral entry csGRP78 predominates during the early stages of respiratory virus infection and facilitates viral internalization through two synergistic mechanisms. On the one hand, csGRP78 acts as a viral co-receptor, directly binding to spike or envelope proteins of respiratory viruses and cooperating with primary receptors (e.g., ACE2) to trigger viral adhesion and endocytosis [32]. On the other hand, it stabilizes the surface expression of host primary receptors, enhances virus-receptor binding affinity, and regulates post-entry viral trafficking and protein folding to further improve infection efficiency [12]. Given its broad regulatory effect on multiple respiratory pathogens, csGRP78 is considered a promising target for broad-spectrum antiviral strategies [45]. csGRP78 functions in viral pneumonia pathogenesis This section focuses on common pneumonia-causing viruses and systematically examines csGRP78’s core role during initial infection stages. Coronavirus infection GRP78 serves as a critical co-receptor and host dependency factor for multiple coronaviruses, including SARS-CoV-2 [12, 13, 32, 60]. csGRP78 directly engages the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein and concurrently forms a ternary complex with host ACE2, with its substrate-binding domain mediating the interaction—a process that substantially enhances viral adhesion and subsequent invasion of alveolar epithelial cells [32]. Clinical evidence demonstrates that circulating GRP78 levels are markedly elevated in COVID-19 patients relative to non-COVID-19 pneumonia patients and healthy controls, and correlate positively with viral load and disease severity [40]. This provides mechanistic insight into the heightened infection risk observed in cancer patients and other csGRP78-high expressing populations [61]. Moreover, coronavirus infection induces GRP78 upregulation through ERS-UPR activation, and intracellular GRP78 promotes the proper folding and assembly of viral structural proteins. GRP78 knockdown or specific inhibition significantly suppresses SARS-CoV-2 replication and enhances antiviral drug efficacy [18]. Orthomyxoviridae (Influenza A Virus) infection GRP78 is essential for influenza A virus infection. csGRP78 directly interacts with viral hemagglutinin (HA) protein, mediating viral adhesion and invasion of alveolar epithelial cells, with HSPA5 knockdown significantly reducing infection efficiency [31, 47, 48]. Influenza infection triggers ERS and markedly upregulates GRP78, which, as a core UPR regulator, participates in infection-induced epithelial damage through PERK-ATF4-CHOP signaling [34, 49, 62]. Flaviviridae and other pneumonia-causing viruses For Flaviviridae viruses with documented pulmonary involvement, csGRP78 serves as a core component of the viral receptor complex, directly binding viral envelope E protein to mediate cellular entry [50, 51]. Additionally, host factor remodeling during DENV infection involves GRP78-E protein interactions at the mitochondria-ER interface, where VDAC relocalization supports viral protein expression and infectious output [63]. GRP78 knockdown or blockade significantly inhibits viral adhesion, entry, and intracellular replication [50–53]. Additionally, GRP78 functions as a required host factor for Ebola virus, chikungunya virus, measles virus, and other pathogens causing pulmonary complications, with GRP78 targeting significantly reducing infection efficiency [54, 59, 64]. In summary, csGRP78 functions as a universal host factor for multiple pneumonia-causing viruses, mediating viral entry and facilitating replication during the initial infection phase [13, 18, 31, 32, 40, 47–56, 58, 59]. This positions csGRP78 as a critical molecular node in disease initiation and a valuable target for early broad-spectrum antiviral intervention. Protective roles and molecular mechanisms of GRP78 in viral pneumonia Beyond its pathogenic roles in viral entry and replication, GRP78 functions as the master regulator of the ERS-UPR pathway and exerts critical endogenous protective effects during viral pneumonia by maintaining cellular homeostasis across multiple lung cell types [39]. This represents the other edge of its "double-edged sword" functionality. GRP78’s protective effects are primarily mediated through maintaining protein folding homeostasis, inhibiting excessive apoptosis, attenuating inflammatory cascades, and preserving the integrity of the pulmonary gas-exchange barrier [65, 66]. The core mechanisms are delineated by cell type below. Protective role of GRP78 in lung parenchymal cells Respiratory virus-induced ERS in alveolar epithelial cells triggers the PERK-eIF2α-ATF4-CHOP apoptotic cascade, leading to epithelial cell death and barrier compromise, ultimately fueling ARDS progression [10, 34]. Acting as a pivotal ER-resident chaperone, GRP78 orchestrates adaptive UPR signaling to mitigate virus-mediated lung injury [33]. Upon viral infection, GRP78 dissociates from UPR sensors and engages misfolded viral proteins, thereby suppressing excessive apoptotic signaling and preserving epithelial barrier integrity [10]. Genetic intervention evidence has confirmed that Grp78 knockdown aggravates alveolar epithelial damage, highlighting the protective potential of GRP78 modulation in parenchymal cell injury [67–69]. GRP78 regulation of lung interstitial and vascular endothelial cells Disruption of the alveolar-capillary barrier underlies pulmonary edema, refractory hypoxemia, and ARDS progression in viral pneumonia, with vascular endothelial injury serving as the key initiating event. By contrast, abnormal fibroblast activation drives post-infectious pulmonary fibrosis [70–72]. In pulmonary vascular endothelial cells, GRP78 sustains ER proteostasis, suppresses ERS-mediated apoptosis and inflammatory activation, preserves endothelial barrier integrity, and attenuates vascular leakage and pulmonary edema [73]. In contrast, pharmacological inhibition of aberrant GRP78-mediated ER stress signaling in acute lung injury models significantly attenuates endothelial inflammation, vascular permeability, and alveolar protein leakage, thereby ameliorating histopathological damage [69]. Additionally, experimental evidence indicates that GRP78-mediated macrophage apoptosis and polarization significantly modulate the fibrotic response in injured lung tissue [74]. In bleomycin-induced pulmonary fibrosis models, Grp78 haploinsufficient mice were strongly protected from fibrosis, exhibiting reduced lung macrophage accumulation and enhanced CHOP-dependent macrophage apoptosis, underscoring that GRP78-driven UPR signaling in the macrophage compartment is a critical determinant of fibrosis progression [74]. Thus, spatiotemporal precision in GRP78/ERS axis regulation represents a critical strategy for preserving gas-exchange barrier integrity and preventing lung injury progression [75]. GRP78 regulation of lung-resident and recruited immune cells GRP78 exhibits functional heterogeneity in immune cell regulation through two primary mechanisms: (1) ER-localized GRP78 (ER-GRP78) modulates immune cell survival, activation, differentiation, and cytokine synthesis via UPR pathways [76]; and (2) csGRP78 participates in pathogen recognition, immune cell homeostasis, and inflammatory signal transduction [13]. The specific regulatory effects vary by immune cell type and infection microenvironment. Macrophages Evidence level: Mixed. High for MDAMs in COVID-19 (clinical + in vivo/in vitro [12, 41, 77]); Medium for AM homeostasis (in vivo/in vitro in endotoxin/asthma models [78–80], not viral pneumonia); Medium for polarization (disease models + in vitro [81–83]). Macrophages are central innate immune effectors in the lung, comprising tissue-resident alveolar macrophages (AMs) and inflammation-recruited monocyte-derived alveolar macrophages (MDAMs), with GRP78 exhibiting distinct regulatory functions in each subset [84]. In alveolar macrophages, csGRP78 serves as a critical regulator of cellular homeostasis and pulmonary immune balance. Lam et al. [78] demonstrated that the pro-apoptotic protein Isthmin-1 (ISM1) binds csGRP78 to selectively induce AM apoptosis, preventing excessive accumulation and spontaneous pulmonary inflammation. Subsequent investigations validated that this pathway substantially mitigates endotoxin-induced acute lung injury and allergic asthma while concurrently enhancing efferocytosis and dampening airway inflammation [79, 80]. In monocytes and MDAMs, csGRP78 facilitates viral entry and drives pro-inflammatory activation. SARS-CoV-2 utilizes csGRP78 for ACE2-independent entry into monocytes and macrophages [12]; csGRP78 expression is significantly elevated in peripheral blood monocytes and lung macrophages from severe COVID-19 patients, correlating positively with pro-inflammatory status and disease severity [12, 41, 77]. Furthermore, GRP78-mediated UPR orchestrates macrophage polarization, whereby IRE1α-XBP1 axis activation promotes glycolytic reprogramming and pro-inflammatory cytokine secretion, thereby exacerbating pulmonary inflammatory injury [85]. Neutrophils Evidence level: Low; indirect evidence from sepsis models involving systemic inflammation, which may not fully recapitulate the focal alveolar injury of viral pneumonia [43, 76, 86]. Neutrophils are the predominant early-infiltrating innate immune cells in viral pneumonia, with excessive activation and neutrophil extracellular trap (NET) formation contributing significantly to lung tissue damage [87, 88]. Direct evidence linking GRP78 to neutrophil function in viral pneumonia remains limited. While ERS-UPR pathways regulate neutrophil survival, migration, and activation via PERK and IRE1α branches in general inflammatory contexts [76], the existing GRP78 data in neutrophils derive primarily from systemic sepsis models rather than focal respiratory viral infection. In these sepsis models, neutrophil GRP78 expression is markedly elevated and correlates with apoptosis [86]; however, systemic inflammation in sepsis differs substantially from the localized alveolar injury seen in viral pneumonia. Rico-Llanos et al. [43] reported a positive correlation between csGRP78 levels and pulmonary inflammation severity, suggesting potential involvement in inflammatory amplification, but direct evidence for GRP78’s role in neutrophil activation and NET formation specifically during viral pneumonia remains lacking. T lymphocytes Evidence level: Medium; clinical observations in severe COVID-19 supported by in vitro mechanistic studies, but direct functional validation in viral pneumonia remains limited [89, 90]. Clinical studies reveal significantly elevated csGRP78 expression on peripheral T cells from severe COVID-19 patients, correlating with T cell activation status, suggesting functional linkage between T cell activation and csGRP78 translocation, though specific regulatory mechanisms remain unclear [89]. Functional studies indicate that ERS via the PERK-ATF4 axis enhances TCR-induced activation in regulatory T cells (Tregs), suggesting that excessive ERS during viral pneumonia may augment Treg immunosuppressive function, contributing to late-phase immunosuppression [90]. Dendritic cells Evidence level: Low; validated exclusively in autoimmune disease models, with no direct evidence in viral pneumonia [91, 92]. ERS-UPR pathways regulate DC antigen processing and presentation efficiency, with UPR branch activation affecting MHC class I presentation of endogenous antigens [92]. Zhou et al. [91] demonstrated that GRP78-treated DCs adopt an immunotolerant phenotype (low CD86/CD40, high B7-H4 expression), inducing Treg differentiation and restoring immune tolerance—effects validated only in autoimmune models, with no direct evidence in viral pneumonia. Table 2Regulatory roles and research evidence of GRP78 in lung immune cellsImmune cell typeLocalizationFunctional effectsKey molecular mechanismsReferencesEvidence levelAMcsGRP78Protective: Maintains population homeostasis, inhibits excessive inflammation, reduces lung injuryBinds ISM1 to induce selective AM apoptosis, preventing excessive accumulation[78–80]Medium (in vivo/in vitro + clinical)Monocytes/MDAMcsGRP78Pathogenic: Mediates viral entry, drives pro-inflammatory activationSARS-CoV-2 enters via ACE2-independent csGRP78 pathway; elevated csGRP78 in severe patients correlates with pro-inflammatory status[12, 41, 77]High (clinical + in vivo/in vitro)Macrophage polarizationER-GRP78Bidirectional: Context-dependent M1/M2 phenotype regulationIRE1α-XBP1 axis promotes M1 pro-inflammatory polarization; PERK axis facilitates M2 repair phenotype[81–83]Medium (disease models + in vitro)NeutrophilsER-GRP78Pathogenic: Promotes activation, inflammatory amplificationERS regulates survival/migration via PERK/IRE1α branches; csGRP78 levels positively correlate with inflammation severity[43, 76, 86]Low (indirect evidence/sepsis models)T LymphocytescsGRP78Bidirectional: Activation upregulation; enhances Treg suppressionElevated csGRP78 on T cells in severe COVID-19; PERK-ATF4 axis enhances TCR-induced Treg activation[89, 90]Medium (clinical + in vivo/in vitro)Dendritic cellsER-GRP78Protective: Induces tolerogenic phenotype, promotes Treg differentiationLow CD86/CD40, high B7-H4 expression inducing immune tolerance and Treg differentiation[91, 92]Low (autoimmune disease models only)B cells/plasma cellsER-GRP78Protective: Maintains antibody synthesis and secretionFunctions as molecular chaperone ensuring proper antibody folding and plasma cell survival[93]Low (physiological/in vitro evidence)Evidence Level Criteria: High: Supported by viral pneumonia/COVID-19 clinical samples with in vivo/in vitro functional validation; Medium: Validated in in vivo/in vitro models but lacks direct pneumonia evidence; Low: Evidence limited to other disease models, in vitro systems, or physiological states without direct pneumonia validation. ACE2, angiotensin-converting enzyme 2; AM, alveolar macrophage; ATF4, Activating transcription factor 4; csGRP78, cell surface glucose-regulated protein 78; DC, Dendritic Cells; ER-GRP78, endoplasmic reticulum GRP78; ERS, endoplasmic reticulum stress; IRE1α, Inositol-requiring enzyme 1α; ISM1, Isthmin-1 (pro-apoptotic protein); M1/M2, Classically activated/alternatively activated macrophage phenotypes; MDAM, monocyte-derived alveolar macrophage; PERK, Protein kinase R-like ER kinase; Treg, regulatory T cell; UPR, unfolded protein response; XBP1, X-box binding protein 1 Table 2Regulatory roles and research evidence of GRP78 in lung immune cellsImmune cell typeLocalizationFunctional effectsKey molecular mechanismsReferencesEvidence levelAMcsGRP78Protective: Maintains population homeostasis, inhibits excessive inflammation, reduces lung injuryBinds ISM1 to induce selective AM apoptosis, preventing excessive accumulation[78–80]Medium (in vivo/in vitro + clinical)Monocytes/MDAMcsGRP78Pathogenic: Mediates viral entry, drives pro-inflammatory activationSARS-CoV-2 enters via ACE2-independent csGRP78 pathway; elevated csGRP78 in severe patients correlates with pro-inflammatory status[12, 41, 77]High (clinical + in vivo/in vitro)Macrophage polarizationER-GRP78Bidirectional: Context-dependent M1/M2 phenotype regulationIRE1α-XBP1 axis promotes M1 pro-inflammatory polarization; PERK axis facilitates M2 repair phenotype[81–83]Medium (disease models + in vitro)NeutrophilsER-GRP78Pathogenic: Promotes activation, inflammatory amplificationERS regulates survival/migration via PERK/IRE1α branches; csGRP78 levels positively correlate with inflammation severity[43, 76, 86]Low (indirect evidence/sepsis models)T LymphocytescsGRP78Bidirectional: Activation upregulation; enhances Treg suppressionElevated csGRP78 on T cells in severe COVID-19; PERK-ATF4 axis enhances TCR-induced Treg activation[89, 90]Medium (clinical + in vivo/in vitro)Dendritic cellsER-GRP78Protective: Induces tolerogenic phenotype, promotes Treg differentiationLow CD86/CD40, high B7-H4 expression inducing immune tolerance and Treg differentiation[91, 92]Low (autoimmune disease models only)B cells/plasma cellsER-GRP78Protective: Maintains antibody synthesis and secretionFunctions as molecular chaperone ensuring proper antibody folding and plasma cell survival[93]Low (physiological/in vitro evidence)Evidence Level Criteria: High: Supported by viral pneumonia/COVID-19 clinical samples with in vivo/in vitro functional validation; Medium: Validated in in vivo/in vitro models but lacks direct pneumonia evidence; Low: Evidence limited to other disease models, in vitro systems, or physiological states without direct pneumonia validation. ACE2, angiotensin-converting enzyme 2; AM, alveolar macrophage; ATF4, Activating transcription factor 4; csGRP78, cell surface glucose-regulated protein 78; DC, Dendritic Cells; ER-GRP78, endoplasmic reticulum GRP78; ERS, endoplasmic reticulum stress; IRE1α, Inositol-requiring enzyme 1α; ISM1, Isthmin-1 (pro-apoptotic protein); M1/M2, Classically activated/alternatively activated macrophage phenotypes; MDAM, monocyte-derived alveolar macrophage; PERK, Protein kinase R-like ER kinase; Treg, regulatory T cell; UPR, unfolded protein response; XBP1, X-box binding protein 1 Regulatory roles and research evidence of GRP78 in lung immune cells Evidence Level Criteria: High: Supported by viral pneumonia/COVID-19 clinical samples with in vivo/in vitro functional validation; Medium: Validated in in vivo/in vitro models but lacks direct pneumonia evidence; Low: Evidence limited to other disease models, in vitro systems, or physiological states without direct pneumonia validation. ACE2, angiotensin-converting enzyme 2; AM, alveolar macrophage; ATF4, Activating transcription factor 4; csGRP78, cell surface glucose-regulated protein 78; DC, Dendritic Cells; ER-GRP78, endoplasmic reticulum GRP78; ERS, endoplasmic reticulum stress; IRE1α, Inositol-requiring enzyme 1α; ISM1, Isthmin-1 (pro-apoptotic protein); M1/M2, Classically activated/alternatively activated macrophage phenotypes; MDAM, monocyte-derived alveolar macrophage; PERK, Protein kinase R-like ER kinase; Treg, regulatory T cell; UPR, unfolded protein response; XBP1, X-box binding protein 1 B cells/plasma cells Evidence level: Low; based on physiological and in vitro evidence only, with no direct viral pneumonia data [93]. Plasma cells, with their high ER protein folding burden from antibody synthesis, critically depend on GRP78 for survival and antibody secretion [93]. However, no direct evidence currently exists for GRP78’s role in regulating B cell activation, antibody class switching, or plasma cell differentiation during viral pneumonia, representing a significant research gap. Table 2 summarizes the regulatory functions of GRP78 across diverse immune cell populations [12, 41, 43, 76–83, 86, 89–93]. Phase-specific dynamics of GRP78 in viral pneumonia progression Viral pneumonia and its progression to ARDS are temporally dynamic pathologies that evolve through three overlapping stages—exudative, proliferative, and fibrotic—each imposing different demands on the ER proteostasis network [94]. We posit that GRP78’s subcellular localization and functional output undergo dynamic shifts across these phases, thereby creating a temporal therapeutic window. Early exudative phase (days 0–7): During initial viral invasion, alveolar epithelial cells mount an adaptive UPR response. ER-GRP78 buffers viral glycoprotein accumulation via PERK-eIF2α-ATF4 signaling and delays CHOP-driven apoptotic programming, thereby maintaining epithelial barrier integrity [10, 34]. Concurrently, stress-triggered surface translocation is initiated, but csGRP78 abundance remains quantitatively limited; we hypothesize that this relative paucity constrains initial viral entry efficiency. Peak inflammatory/proliferative phase (days 7–14): As viral replication overwhelms ER folding capacity, the UPR switches from adaptive to terminal. Sustained PERK-ATF4-CHOP signaling and IRE1α-XBP1 hyperactivation drive alveolar epithelial apoptosis and M1 macrophage glycolytic reprogramming, amplifying pulmonary inflammation [34, 85]. Post-mortem analyses reveal peak GRP78 expression in pneumocytes and lung macrophages during severe COVID-19, at which point csGRP78-mediated viral entry and pro-inflammatory signaling predominate [41]. This is the phase where GRP78’s pathogenic face prevails, and targeted inhibition of surface GRP78 or IRE1α may be most warranted. Late resolution or fibrotic phase (> 14 days): In survivors, ER stress must resolve to permit tissue repair. ER-GRP78 in alveolar epithelial progenitors regulates cellular senescence and fibrotic remodeling; loss of GRP78 in AT2 cells drives spontaneous fibrosis, whereas CHOP-dependent macrophage apoptosis protects against fibrotic progression [68, 74]. However, persistent GRP78/UPR signaling in the macrophage compartment may perpetuate fibrotic remodeling [74]. Thus, late-phase GRP78 activity transitions from inflammation back to repair, but its persistence may tip the balance toward post-infectious pulmonary fibrosis. This phase-specific framework carries direct clinical implications: early enhancement of ER-GRP78 chaperone activity may protect the epithelial barrier; mid-phase blockade of csGRP78 or IRE1α hyperactivation may curb viral propagation and cytokine storms; and late-phase resolution of persistent ER stress may prevent fibrotic sequelae. Current status of GRP78-targeted drug development The development of GRP78-targeted therapeutics has expanded rapidly across oncology, metabolic disorders, and fibrotic diseases [10, 20, 95]. Yet when viewed through the lens of viral pneumonia, the landscape narrows considerably. Most candidate agents have never been tested in respiratory viral infection models, and the few existing preclinical data derive largely from SARS-CoV-2 studies [96]. Nevertheless, the mechanistic diversity of these compounds—ranging from direct chaperone inhibition to csGRP78 blockade and post-translational modulation—offers a translational roadmap for future antiviral drug design. Table 3 summarizes major therapeutic agents targeting GRP78 function and advances in their mechanisms of action over the past five years [15, 18, 28, 29, 97–102]. Table 3GRP78-targeted therapeutics with relevance to viral pneumonia: mechanisms and translational statusDrug/agentTarget/pathwayCore mechanismDisease contextRelevance to viral pneumoniaRefStageHA15GRP78 chaperone activityInhibits GRP78; synergizes with nirmatrelvirSARS-CoV-2 infectionDirect antiviral and anti-inflammatory efficacy in hamster lung model[18]Preclinical76-E6 mAbcsGRP78-CD44vBlocks Src signalingTriple-negative breast cancerTheoretical viral entry blockade; no respiratory data[28]In vitroC38 mAb / inhibitory peptidecsGRP78-α2M*Inhibits YAP/TAZ fibrotic signalingKidney fibrosisPotential to block csGRP78 viral co-receptor function; no viral model tested[29]Animal modelsW1-R9 peptidecsGRP78-mediated endocytosisDelivers siRNA via receptor-mediated uptakeProstate cancerProof-of-concept for receptor-mediated uptake in cancer cells; pulmonary delivery and antiviral application untested[97]In vitroGRP78 siRNA/shRNAGRP78 expression (post-transcriptional)Silences GRP78; enhances antiviral drug activityLiver cancer drug resistance; SARS-CoV-2Adjunct to direct-acting antivirals; systemic toxicity concerns[18, 98]In vitro/animalBOLD-100GRP78 transcriptional activationSuppresses UPR; induces CHOP/ROSPancreatic cancerTheoretical ERS attenuation in alveolar epithelium; pulmonary safety unknown[99]PreclinicalC5-PE38csGRP78-positive cellsInduces immunogenic cell death; activates STINGColorectal cancer/melanomaConceptual STING-mediated antiviral immune enhancement[100]Animal modelsSinensetinGRP78/CHOP axisDirect binding to GRP78; attenuates ER stressHepatic ischemia–reperfusionERS cytoprotection mechanism applicable to lung epithelium; no infection data[15]Animal modelsRosmarinic acidGRP78/PERK/MANF axisModulates ER stress signalingEndotoxin-induced neuronal injuryAnti-inflammatory ERS modulation; lung bioavailability untested[101]Animal modelsNaHSGRP78 Cys420 S-sulfhydrationActivates IRE1α; promotes M1 macrophage polarizationBreast cancerPotential to enhance alveolar macrophage viral clearance; no pulmonary data[102]Animal modelscsGRP78, cell surface glucose-regulated protein 78; UPR, unfolded protein response; ERS, endoplasmic reticulum stress; YAP/TAZ, yes-associated protein/transcriptional co-activator with PDZ-binding motif; STING, stimulator of interferon genes; ROS, reactive oxygen species Table 3GRP78-targeted therapeutics with relevance to viral pneumonia: mechanisms and translational statusDrug/agentTarget/pathwayCore mechanismDisease contextRelevance to viral pneumoniaRefStageHA15GRP78 chaperone activityInhibits GRP78; synergizes with nirmatrelvirSARS-CoV-2 infectionDirect antiviral and anti-inflammatory efficacy in hamster lung model[18]Preclinical76-E6 mAbcsGRP78-CD44vBlocks Src signalingTriple-negative breast cancerTheoretical viral entry blockade; no respiratory data[28]In vitroC38 mAb / inhibitory peptidecsGRP78-α2M*Inhibits YAP/TAZ fibrotic signalingKidney fibrosisPotential to block csGRP78 viral co-receptor function; no viral model tested[29]Animal modelsW1-R9 peptidecsGRP78-mediated endocytosisDelivers siRNA via receptor-mediated uptakeProstate cancerProof-of-concept for receptor-mediated uptake in cancer cells; pulmonary delivery and antiviral application untested[97]In vitroGRP78 siRNA/shRNAGRP78 expression (post-transcriptional)Silences GRP78; enhances antiviral drug activityLiver cancer drug resistance; SARS-CoV-2Adjunct to direct-acting antivirals; systemic toxicity concerns[18, 98]In vitro/animalBOLD-100GRP78 transcriptional activationSuppresses UPR; induces CHOP/ROSPancreatic cancerTheoretical ERS attenuation in alveolar epithelium; pulmonary safety unknown[99]PreclinicalC5-PE38csGRP78-positive cellsInduces immunogenic cell death; activates STINGColorectal cancer/melanomaConceptual STING-mediated antiviral immune enhancement[100]Animal modelsSinensetinGRP78/CHOP axisDirect binding to GRP78; attenuates ER stressHepatic ischemia–reperfusionERS cytoprotection mechanism applicable to lung epithelium; no infection data[15]Animal modelsRosmarinic acidGRP78/PERK/MANF axisModulates ER stress signalingEndotoxin-induced neuronal injuryAnti-inflammatory ERS modulation; lung bioavailability untested[101]Animal modelsNaHSGRP78 Cys420 S-sulfhydrationActivates IRE1α; promotes M1 macrophage polarizationBreast cancerPotential to enhance alveolar macrophage viral clearance; no pulmonary data[102]Animal modelscsGRP78, cell surface glucose-regulated protein 78; UPR, unfolded protein response; ERS, endoplasmic reticulum stress; YAP/TAZ, yes-associated protein/transcriptional co-activator with PDZ-binding motif; STING, stimulator of interferon genes; ROS, reactive oxygen species GRP78-targeted therapeutics with relevance to viral pneumonia: mechanisms and translational status csGRP78, cell surface glucose-regulated protein 78; UPR, unfolded protein response; ERS, endoplasmic reticulum stress; YAP/TAZ, yes-associated protein/transcriptional co-activator with PDZ-binding motif; STING, stimulator of interferon genes; ROS, reactive oxygen species Direct antiviral strategies against respiratory viral infections Small-molecule GRP78 inhibitors Among small-molecule inhibitors, HA15 stands out as the only agent with validated antiviral efficacy in a coronavirus pneumonia model. HA15 selectively targets GRP78 and abrogates its chaperone function [18]. In a recent preclinical investigation, co-administration of HA15 with the SARS-CoV-2 main protease inhibitor nirmatrelvir suppressed replication of both wild-type and Omicron variants with superior efficacy compared to either agent used as monotherapy [18]. Notably, in hamster models, this combination ameliorated virus-induced pulmonary atelectasis and interstitial inflammation, indicating that GRP78 inhibition can concurrently suppress viral propagation while mitigating lung parenchymal injury [18]. These findings position HA15 as a proof-of-concept compound for GRP78-targeted antiviral therapy, though its pharmacokinetic profile and safety in human lung tissue remain undefined. csGRP78-targeted biologics and viral entry blockade Given the central role of csGRP78 in mediating viral attachment and invasion, biologics that disrupt csGRP78 function represent a logical antiviral strategy [103]. The monoclonal antibody 76-E6 specifically targets csGRP78 and blocks its interaction with CD44v, thereby inhibiting downstream Src signaling [28]. Although currently evaluated in triple-negative breast cancer, its mechanism—steric hindrance of csGRP78-ligand binding—mirrors the theoretical requirements for blocking SARS-CoV-2 spike protein engagement. Similarly, the C38 neutralizing antibody and its derivative inhibitory peptide prevent csGRP78 from binding activated α2-macroglobulin (α2M*), suppressing YAP/TAZ-driven fibrotic signaling [29]. In the context of viral pneumonia, such antibodies could theoretically prevent csGRP78 from serving as a viral co-receptor, yet direct antiviral efficacy data are entirely absent. The W1-R9 peptide exploits csGRP78-mediated endocytosis for receptor-directed siRNA delivery, but this has been demonstrated only in prostate cancer cell lines; pulmonary delivery and antiviral efficacy remain entirely speculative [97]. GRP78 gene silencing as an antiviral adjunct RNA interference strategies offer another avenue. GRP78-specific siRNA substantially enhanced nirmatrelvir’s anti-SARS-CoV-2 activity in vitro [18], while shRNA-mediated GRP78 downregulation disrupts the CD44-GRP78-IGF-1R signaling axis [98]. These gene-silencing approaches underscore that lowering GRP78 abundance can potentiate conventional antivirals. However, systemic GRP78 silencing carries substantial risk, given the protective role of ER-GRP78 in maintaining alveolar epithelial homeostasis [10]. Any clinical translation would require cell-specific or lung-targeted delivery systems to avoid compromising host defense. Mechanistic paradigms from non-infectious models with potential pulmonary translation Because dedicated antiviral GRP78 modulators remain scarce, insights from adjacent disease models may inform future drug development for viral pneumonia—provided their mechanisms are carefully contextualized and their limitations explicitly acknowledged. UPR modulation and ER stress attenuation BOLD-100, a GRP78-specific inhibitor originally developed for pancreatic ductal adenocarcinoma, suppresses GRP78-mediated transcriptional activation of the UPR and triggers CHOP-dependent apoptosis through ROS generation and R-loop accumulation [99]. In viral pneumonia, sustained UPR activation drives alveolar epithelial apoptosis via the PERK-eIF2α-ATF4-CHOP axis. Theoretically, pharmacological UPR suppression by BOLD-100 could attenuate this injury cascade. Yet a critical caveat exists: moderate UPR activation is adaptive and essential for resolving ER protein overload during viral replication. Blunt UPR inhibition might therefore impair host cell survival rather than protect it, and the therapeutic window in pulmonary cells is unknown. STING pathway activation and immune microenvironment remodeling The GRP78-targeting nanobody-immunotoxin conjugate C5-PE38 induces immunogenic cell death and activates the STING pathway in tumor models [100]. STING signaling is a cornerstone of antiviral innate immunity, driving type I interferon production and dendritic cell maturation. While C5-PE38 itself is cytotoxic and unsuitable for direct antiviral use, its ability to couple GRP78 targeting with STING activation raises the possibility of engineered csGRP78-directed STING agonists that could enhance pulmonary antiviral responses without systemic toxicity. This remains purely conceptual. Natural products targeting grp78-mediated ER stress Several natural products modulate GRP78 activity with cytoprotective effects. Sinensetin directly binds GRP78 and attenuates CHOP-mediated ER stress, reducing hepatocyte apoptosis in ischemia–reperfusion models [15]. Rosmarinic acid interacts with GRP78 to modulate the PERK/MANF axis and ameliorates endotoxin-induced neuronal injury [101]. Both compounds act through GRP78-dependent ER stress attenuation—a mechanism directly relevant to virus-induced alveolar epithelial damage. However, their efficacy in lung tissue, bioavailability via inhalation, and interactions with viral replication cycles have not been examined. Post-translational modulation of GRP78 and macrophage polarization The hydrogen sulfide donor NaHS mediates S-sulfhydration of GRP78 at cysteine 420, promoting its dissociation from IRE1α and activating the IRE1α pathway [102]. This modification drives tumor-associated macrophage polarization toward the M1 phenotype. In viral pneumonia, alveolar macrophages are pivotal early responders; M1 polarization generally supports viral clearance through pro-inflammatory cytokine production and antigen presentation [104]. Whether NaHS or similar sulfhydration-modulating agents can redirect pulmonary macrophage fate via GRP78 remains an open question, but the mechanistic parallel is intriguing. Critical research gaps Translational gap analysis. Before GRP78-targeted agents can enter clinical trials, three quantifiable gaps must be addressed. First, pulmonary bioavailability: the only preclinical pulmonary efficacy data derive from hamster models [18], and no pharmacokinetic profiles exist for inhaled biologics or nanoparticles in human lung tissue. Distal alveolar deposition faces mucociliary clearance, alveolar macrophage uptake, and surfactant-layer barriers, while systemic absorption—though reduced—remains non-negligible, risking off-target suppression of constitutive ER chaperones [10]. Second, molecular selectivity: global GRP78 inhibition dismantles protective ER chaperone networks in uninfected epithelium; future agents must discriminate between ER-GRP78 and csGRP78, or be pharmacologically restricted to the hyperinflammatory phase when csGRP78 is maximally surface-exposed [10, 41]. Third, intervention timing: early blockade risks suppressing adaptive PERK-eIF2α signaling essential for epithelial survival, whereas late blockade may miss the narrow csGRP78-mediated viral entry window; the precise temporal relationship between viral replication kinetics, surface GRP78 exposure, and inflammatory amplification remains undefined [34]. In summary, GRP78-targeted drug development for viral pneumonia is still in its infancy. The field must move beyond mechanistic extrapolation from oncology models and generate lung-specific, virus-specific efficacy and safety data to realize the therapeutic potential of this unique molecular target. Research trends, clinical translation and future perspectives GRP78 as a clinical biomarker: current evidence and limitations For a review targeting clinical and experimental translation, it is essential to appraise how close GRP78 is to bedside use. Current clinical evidence is largely retrospective and fragmented. In COVID-19 pneumonia, serum GRP78 levels are significantly elevated in patients with radiographically confirmed pneumonia compared to non-pneumonia controls [40]. A two-cohort retrospective study (n = 180) reported that serum GRP78 predicted pneumonia with an AUC of approximately 0.71, a modest discriminative performance that underscores the need for combinatorial biomarker strategies [37]. Similarly, a case–control study found that COVID-19 pneumonia patients had higher serum GRP78 than non-COVID pneumonia or CT-negative controls, with only a weak-positive correlation to CRP (r = 0.223, p = 0.008) [40]. Post-mortem studies have documented highly elevated GRP78 in pneumocytes and lung macrophages, but tissue biopsy is obviously not viable for prognostic monitoring [41]. A principal barrier to clinical translation remains the absence of standardized assay platforms. Serum GRP78 quantification typically relies on ELISA; however, a multi-center study employing different commercial kits (Gentaur versus Sun Long) reported substantially divergent absolute GRP78 concentrations across cohorts, highlighting that both assay variability and population heterogeneity confound cross-study comparability [37]. Beyond serum, GRP78 is detectable in bronchoalveolar lavage fluid (BALF), with increased secretion documented in cigarette smokers, suggesting local lung epithelial release under stress conditions [105]; however, BALF collection is invasive and impractical for routine screening. Thus, the optimal specimen type—serum for accessibility, BALF for local specificity, or tissue for definitive pathological confirmation—remains unresolved. Head-to-head comparisons with established biomarkers further highlight GRP78’s current limitations. In a diagnostic cohort of sepsis, serum GRP78 yielded an AUC of 0.771 for diagnosis, outperforming IL-6 (0.701) and lactate (0.674) but falling short of procalcitonin (PCT, 0.910) and CRP (0.802) [106]. Notably, the combination of GRP78 and CHOP improved diagnostic accuracy (AUC 0.852), suggesting that an ER stress biomarker panel—rather than GRP78 alone—might offer clinically meaningful value [106]. To date, no prospective study has validated a GRP78-based algorithm for risk stratification in viral pneumonia, nor has any trial established validated cutoff thresholds, dynamic monitoring protocols, or turnaround times compatible with emergency department workflows. In summary, while GRP78 is biologically plausible as a stress biomarker, it remains at the preclinical-to-clinical interface: standardized assays, prospective validation, and combinatorial modeling with existing markers are essential before it can inform routine bedside practice. Research trends and future perspectives In viral pneumonia research, GRP78 investigations are advancing toward precision medicine through three key directions: mechanistic refinement, targeted therapeutics, and pathological expansion. Mechanistically, research has shifted from general GRP78 functions to dissecting the distinct roles of ER-GRP78 versus csGRP78 across pulmonary cell types, establishing a foundation for cell-specific interventions [107]. Therapeutically, leveraging csGRP78’s disease-specific surface expression, novel targeted formulations such as the GRP78 inhibitor HA15 are emerging alongside combination strategies—exemplified by the synergistic anti-SARS-CoV-2 activity of HA15 and nirmatrelvir observed in preclinical models [18]. Pathologically, studies now explore GRP78’s regulatory roles across the disease continuum, including viral pneumonia complications such as pulmonary fibrosis and ARDS, enabling multi-stage therapeutic approaches [67]. Despite progress, the molecular switch governing GRP78’s functional polarity remains inadequately defined. We propose an integrated, stage-dependent model in which GRP78 transitions from protective to pathogenic based on four converging cues. First, viral load thresholds: at low viral burden, ER-GRP78 mounts adaptive PERK-eIF2α-ATF4 signaling to preserve epithelial protein homeostasis [34]; once viral protein load exceeds ER folding capacity, sustained UPR activation shifts toward IRE1α-XBP1 and CHOP-driven apoptotic programming, and GRP78 upregulation paradoxically facilitates viral replication [31, 34]. Second, post-translational modification dynamics: cancer studies suggest that S-palmitoylation may alter GRP78 subcellular trafficking and O-glycosylation may modulate its ER retention [25, 26]; we hypothesize that similar modifications in infected lung cells could expand the csGRP78 pool. Third, UPR branch selectivity: the PERK axis predominantly mediates early protective translational attenuation, whereas late-phase IRE1α hyperactivation drives pro-inflammatory output, as suggested by cancer models [102]; the relative flux through each branch may determine whether GRP78 sustains cell survival or accelerates lung injury [34]. Fourth, microenvironmental stress: inflammatory hypoxia generates ROS that disrupts ER redox homeostasis and amplifies ERS [36, 108], while ER stress itself triggers unconventional trafficking of GRP78 to the cell surface, bypassing classical retrieval [109]. We further hypothesize that acidic and oxidatively stressed niches in infected alveoli—akin to the tumor microenvironment—may synergistically promote this surface translocation. This model generates testable predictions: staged viral infection experiments could define the MOI threshold for PERK-to-IRE1α switching; site-specific PTM mutants could dissect whether blocking GRP78 palmitoylation or glycosylation shifts the ER-to-surface balance; and organoid-based pH/ROS mapping could directly test whether local acidification and oxidative stress correlate with csGRP78 abundance and viral entry efficiency. Translational bottlenecks: from bench to bedside While GRP78-targeted strategies hold theoretical promise, three real-world hurdles must be addressed before clinical translation. First, pulmonary delivery and systemic toxicity. The only preclinical pulmonary efficacy data for GRP78-targeted antiviral therapy come from hamster models, where HA15 combined with nirmatrelvir alleviated virus-induced pulmonary atelectasis and interstitial inflammation [18]. However, these data provide no pharmacokinetic profile for human lung tissue, and systemic GRP78 inhibition carries substantial risk given the protective role of ER-GRP78 in maintaining alveolar epithelial homeostasis. Inhaled biologics and nanoparticles offer a logical route to achieve high local concentrations while minimizing systemic exposure, yet distal lung deposition faces formidable anatomical barriers: mucociliary clearance, alveolar macrophage uptake, and the surfactant layer limit the fraction of inhaled macromolecules reaching the alveolar epithelium. Second, the therapeutic window of csGRP78 surface expression. csGRP78 is minimally expressed on the surface of healthy pulmonary epithelium under baseline conditions, but is markedly upregulated during ER stress and viral infection [10]. This differential expression creates a potential targeting window. Yet the temporal dynamics remain poorly defined: in severe COVID-19, peak GRP78 expression in pneumocytes and lung macrophages coincides with advanced epithelial injury and widespread inflammation [41], meaning that therapeutic intervention may need to occur early—before maximal surface exposure—to prevent viral entry. Conversely, premature blockade of csGRP78 during the initial adaptive phase might inadvertently suppress protective signaling. Third, resistance and compensatory mechanisms. In the broader context of ER stress biology, pharmacological suppression of one UPR branch often triggers compensatory activation of alternative branches—most notably ATF6 or HSP70-dependent rescue pathways—that can restore protein folding capacity and sustain cell survival [34]. Analogous compensatory remodeling may occur in virally infected lung cells: if GRP78 is inhibited, residual viral glycoproteins could activate ATF6 or other chaperone networks, potentially blunting antiviral efficacy and paradoxically extending the ER stress window.